SPOTLIGHT -
Dr. Dean on the Potential Role of Consolidative CAR T-Cell Therapy in MCL
Robert M. Dean, MD, discusses the potential role for consolidative CAR T-cell therapy in mantle cell lymphoma.
Read More
Dr. Dean on Remaining Challenges in DLBCL
Robert M. Dean, MD, discusses remaining challenges in diffuse large B-cell lymphoma.
Dr. Dean on Challenges in the MCL Paradigm
Robert Dean, MD, staff physician, Cleveland Clinic, discusses challenges in the mantle cell lymphoma (MCL) paradigm.
Dr. Dean on FDA Approved Drugs for Patients With Relapsed MCL
Robert Dean, MD, staff physician, Cleveland Clinic, discusses FDA approved drugs for patients with relapsed mantle cell lymphoma.
Dr. Dean Discusses Ongoing Research on Biomarkers in MCL
Robert Dean, MD, a staff physician at Cleveland Clinic, discusses ongoing research on biomarkers in mantle cell lymphoma (MCL).
Dr. Dean on the Evolution of Treatment Approaches in MCL
Robert Dean, MD, staff physician, Cleveland Clinic, discusses the evolution of treatment approaches in mantle cell lymphoma (MCL).
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
